NasdaqGS:PHVSPharmaceuticals
Robust RAPIDe-3 Deucrictibant Data Might Change The Case For Investing In Pharvaris (PHVS)
Earlier in June 2026, Pharvaris reported Phase 3 RAPIDe-3 data and long-term extension results at EAACI, highlighting rapid symptom relief, sustained hereditary angioedema control, and supportive cardiovascular safety findings for oral deucrictibant in both on-demand and prophylactic use.
An especially interesting insight was that nearly half of interviewed RAPIDe-3 participants described an improved day-to-day treatment experience with oral deucrictibant versus prior injectable therapies,...

